Zobrazeno 1 - 10
of 38
pro vyhledávání: '"G S, Geis"'
Publikováno v:
Alimentary Pharmacology & Therapeutics. 16:819-827
Aim: To compare celecoxib (800 mg/day, n=1997) with diclofenac (150 mg/day, n=1996) on dyspepsia-related tolerability. Methods: In one of the two protocols comprising the Celecoxib Long-Term Arthritis Safety Study, a randomized double-blind trial, pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::710dc267c4d91321ef63439c013a9887
https://doi.org/10.1046/j.1365-2036.2002.01219.x
https://doi.org/10.1046/j.1365-2036.2002.01219.x
Publikováno v:
American Journal of Therapeutics. 8:49-64
Nonsteroidal anti-inflammatory drugs have been a mainstay in the treatment of inflammatory diseases such as rheumatoid arthritis. However, these agents can result in severe and occasionally life-threatening adverse effects that can limit therapeutic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2171eb51c5a52510bf534cec75d02c41
https://doi.org/10.1097/00045391-200101000-00009
https://doi.org/10.1097/00045391-200101000-00009
Publikováno v:
Scandinavian Journal of Rheumatology. 30:11-18
Objective: A clinical trial was conducted in 600 patients with OA of the knee to test the hypothesis that the specific COX-2 inhibitor, celecoxib, has equivalent efficacy and a superior tolerability/safety profile when compared to diclofenac, the cur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9423ee9dd924b1219f5e3da4bfa16daf
https://doi.org/10.1080/030097401750065265
https://doi.org/10.1080/030097401750065265
Autor:
Jay L. Goldstein, J Kaiser, C J Maurath, Naurang M. Agrawal, Kenneth M. Verburg, Richard C. Hubbard, G S Geis, Fred E. Silverstein
Publikováno v:
American Journal of Gastroenterology. 95:1681-1690
The aim of this study was to assess the rate of upper gastrointestinal (UGI) ulcer complications (bleeding, perforation, or gastric outlet obstruction) associated with celecoxib, a specific COX-2 inhibitor, compared with the rate associated with nons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d9837532df46f3d930d99c04b2169a2
https://doi.org/10.1111/j.1572-0241.2000.02194.x
https://doi.org/10.1111/j.1572-0241.2000.02194.x
Publikováno v:
American Journal of Therapeutics. 7:159-174
The novel cyclooxygenase- (COX)-2 inhibitor celecoxib is an effective treatment for the signs and symptoms of osteoarthritis and rheumatoid arthritis. Conventional treatment for these debilitating conditions routinely involves the use of conventional
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::81747a11fe8f642a840990cbf966c0cc
https://doi.org/10.1097/00045391-200007030-00004
https://doi.org/10.1097/00045391-200007030-00004
Autor:
Gary W. Williams, R C Hubbard, R E Ettlinger, S S Yu, W Zhao, M E Lonien, Eric Ruderman, G S Geis
Publikováno v:
JCR: Journal of Clinical Rheumatology. 6:65-74
A previous study has shown celecoxib 100 mg b.i.d. to be comparably effective to naproxen 500 mg b.i.d. in treating osteoarthritis (OA). The primary objective of this study was to compare the efficacy of a once-daily regimen of celecoxib (200 mg q.d.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a86ab90e17ab320d61397ca759d88614
https://doi.org/10.1097/00124743-200004000-00002
https://doi.org/10.1097/00124743-200004000-00002
Autor:
G S Geis
Publikováno v:
Scandinavian Journal of Rheumatology. 28:31-37
Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective for the relief of pain and inflammation, yet their use is tempered by the development of side effects, primarily in the gastrointestinal (GI) tract. It is now known that inhibition of the en
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3bd07dcaec60cc33b37c9e6781dea6fb
https://doi.org/10.1080/030097499750042407
https://doi.org/10.1080/030097499750042407
Autor:
G S Geis, Lanza Fl, Lee S. Simon, Peter C. Isakson, Benjamin D. Schwartz, Peter E. Lipsky, Richard C. Hubbard, Talwalker S
Publikováno v:
Arthritis & Rheumatism. 41:1591-1602
Objective To investigate the efficacy and safety of SC-58635 (celecoxib), an antiinflammatory and analgesic agent that acts by selective cyclooxygenase 2 (COX-2) inhibition and is not expected to cause the typical gastrointestinal (GI), renal, and pl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3738339ff5371f3d84dd6c3edd7d60a3
https://doi.org/10.1002/1529-0131(199809)41:9<1591::aid-art9>3.0.co
https://doi.org/10.1002/1529-0131(199809)41:9<1591::aid-art9>3.0.co
Publikováno v:
Annals of the Rheumatic Diseases. 52:881-885
OBJECTIVES--To compare the efficacy and gastroduodenal safety of a fixed-dose combination of diclofenac sodium 50 mg and misoprostol 200 micrograms twice daily with those of piroxicam 10 mg twice daily and naproxen 375 mg twice daily in patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d94479dd1cf8c7ce7f8df0f94e4b256a
https://doi.org/10.1136/ard.52.12.881
https://doi.org/10.1136/ard.52.12.881
Autor:
G. S. Geis
Publikováno v:
Scandinavian Journal of Rheumatology. 21:33-36
Data from four double-blind studies of the treatment of patients with rheumatoid arthritis or osteoarthritis were combined. For 4 to 12 weeks, 747 patients received Arthrotec, a combination of 50 mg of diclofenac and 200 micrograms of misoprostol, an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::330b59dbcb995166920852218e5892a2
https://doi.org/10.3109/03009749209095097
https://doi.org/10.3109/03009749209095097